Anthracycline News and Research

RSS
Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.
Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Biomarkers can increase success rate of clinical trials for breast cancer drugs by almost 50%

Biomarkers can increase success rate of clinical trials for breast cancer drugs by almost 50%

Most basal-like breast and ovarian tumors have similar genetic origins

Most basal-like breast and ovarian tumors have similar genetic origins

Cell Therapeutics launches Pixuvri in the European Union

Cell Therapeutics launches Pixuvri in the European Union

Arsenic induces acute promyelocytic leukemia remission

Arsenic induces acute promyelocytic leukemia remission

Chemotherapy during pregnancy: an interview with Professor Sibylle Loibl

Chemotherapy during pregnancy: an interview with Professor Sibylle Loibl

Study examines whether eribulin offers added benefit to women with breast cancer

Study examines whether eribulin offers added benefit to women with breast cancer

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

CTI announces results from PIX301 phase 3 trial of Pixuvri for NHL

CTI announces results from PIX301 phase 3 trial of Pixuvri for NHL

EC approves CTI’s Pixuvri to treat multiply relapsed or refractory aggressive NHL

EC approves CTI’s Pixuvri to treat multiply relapsed or refractory aggressive NHL

New light on many biological differences between individual breast cancers

New light on many biological differences between individual breast cancers

Mutational profiling could determine which AML patients will benefit from dose-intensive chemotherapy

Mutational profiling could determine which AML patients will benefit from dose-intensive chemotherapy

Study finds subtle cognitive deficits in women treated with CMF chemotherapy

Study finds subtle cognitive deficits in women treated with CMF chemotherapy

EMA CHMP recommends CTI's Pixuvri for conditional approval

EMA CHMP recommends CTI's Pixuvri for conditional approval

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Cell Therapeutics voluntarily withdraws Pixuvri NDA for NHL

Cell Therapeutics voluntarily withdraws Pixuvri NDA for NHL

EMA CHMP may issue an opinion on CTI's Pixuvri MAA in mid-Feb.

EMA CHMP may issue an opinion on CTI's Pixuvri MAA in mid-Feb.

Chemotherapy drugs can lead to relapse of leukemia

Chemotherapy drugs can lead to relapse of leukemia